Nicalin: A Potential Drug Target for Cancer and Other Diseases

Target Name: NCLN

NCBI ID: G56926

NCLN

Nicalin: A Potential Drug Target for Cancer and Other Diseases

Nicalin (ISO Form 1) is a drug target and a biomarker that is being studied for its potential utility in treating various diseases, including cancer. Nicalin is a purine nucleoside that is derived from the Asian green creeper plant. It has been shown to have anti-inflammatory and antioxidant properties and has been found to be expressed in various tissues and organs, including the brain, heart, liver, and pancreas.

One of the main reasons for the potential utility of nicalin as a drug target is its ability to interact with multiple intracellular signaling pathways, including those involved in cell growth, apoptosis, and inflammation. Nicalin has been shown to inhibit the activity of the protein kinase A (PKA), which is involved in cell growth and survival. It also inhibits the activity of the transcription factor NF-kappa-B, which is involved in inflammation.

In addition to its ability to inhibit the activity of PKA and NF-kappa-B, nicalin has also been shown to interact with the protein tyrosine kinase (TK) kinase, which is involved in the regulation of cell growth and apoptosis. This interaction may have implications for the development of cancer, as the regulation of cell growth and apoptosis is a critical aspect of the disease.

Nicalin has also been shown to have anti-inflammatory effects, which may be beneficial in the treatment of various inflammatory diseases, including cancer. Chronic inflammation has been linked to the development and progression of a number of diseases, including heart disease, cancer, and rheumatoid arthritis.

In addition to its anti-inflammatory properties, nicalin has also been shown to have antioxidant properties. It has been shown to have a high antioxidant capacity and to protect cells from oxidative stress. This may be beneficial in the treatment of diseases that are characterized by oxidative stress, such as cancer.

Nicalin has also been shown to have potential benefits in the treatment of certain neurological disorders, including Parkinson's disease and Alzheimer's disease. In these disorders, the levels of nicalin have been shown to be decreased, and its levels have been shown to be increased in the brains of individuals with these disorders. This may indicate that nicalin may have potential as a treatment for these disorders.

In conclusion, nicalin is a drug target and biomarker that has potential utility in treating a variety of diseases, including cancer. Its ability to interact with multiple intracellular signaling pathways and its anti-inflammatory and antioxidant properties make it a promising candidate for further study. Further research is needed to fully understand the potential benefits and risks of nicalin as a drug.

Protein Name: Nicalin

Functions: Component of the multi-pass translocon (MPT) complex that mediates insertion of multi-pass membrane proteins into the lipid bilayer of membranes (PubMed:36261522, PubMed:32820719). The MPT complex takes over after the SEC61 complex: following membrane insertion of the first few transmembrane segments of proteins by the SEC61 complex, the MPT complex occludes the lateral gate of the SEC61 complex to promote insertion of subsequent transmembrane regions (PubMed:36261522). May antagonize Nodal signaling and subsequent organization of axial structures during mesodermal patterning, via its interaction with NOMO (By similarity)

The "NCLN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCLN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets